Palisade Bio (PALI) Stock Price, Quote, News & History | Benzinga

SPY779.27+0.57%QQQ759.84+0.48%BTC/USD85,591.26−0.18%DIA514.48+0.46%GLD382.02+0.65%TLT77.29+0.23%

Palisade Bio Inc (PALI) Stock Price, Quote, News & History

PALINASDAQ

Trade with Public

Trade with Public

$1.50

0.0352.4%

Last update: Oct 6, 3:53 PM

$1.53

0.074.79%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$1.51

Close

-

Volume / Avg.

1.76M / 2.73M

Day Range

$1.47 - $1.55

52 Wk Range

1.32 - 2.86

Market Cap

$260.53M

P/E Ratio

2.25

Dividend Yield

-

Exchange

NASDAQ

RSI

38

Short Interest

17.37%

Days to Cover

13.76

Recent Palisade Bio Inc News

ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.

Avi Kapoor

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.

Vandana Singh

This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.

Avi Kapoor

Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include Zscaler, Brain, LG Display, Zepp Health, Globalfoundries, Posco Holdings, Insulet, Palisade Bio, Satellogic, and Box.

Avi Kapoor

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-18.19M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

137.97M

Free Cash Flow (TTM)

-18.19M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

119.78M

Analyst Trends and Forecast

1

Apr

1

Jul

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$122.29M

PE Ratio (TTM)

2.25

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

464.51

PB Ratio (TTM)

2.10

Earnings Yield % (TTM)

44.37%

Earnings Yield % (FWD)

-16.38%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.70

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$125.17M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-$311.00K